Cdk6 Antibody (H-11): sc-271364
- Cdk6 Antibody (H-11) is a mouse monoclonal IgG3 κ, cited in 6 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 291-326 at the C-terminus of Cdk6 of human origin
- recommended for detection of Cdk6 of human origin by WB, IP, IF and ELISA
- See Cdk6 (DCS-83): sc-53638 for Cdk6 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG3 BP-HRP is the preferred secondary detection reagent for Cdk6 Antibody (H-11) for WB applications. This reagent is now offered in a bundle with Cdk6 Antibody (H-11) (see ordering information below).
Cdk6 Antibody (H-11) is a mouse monoclonal IgG3 antibody that detects Cdk6 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Cdk6 is a crucial member of the cyclin-dependent kinase (Cdk) family, which plays a vital role in regulating the cell cycle, particularly during the G1/S transition. anti-Cdk6 antibody (H-11) targets a protein primarily located in the nucleus, where Cdk6 associates with cyclins D1, D2, and D3 to phosphorylate target substrates that drive cell cycle progression. Proper functioning of Cdk6 is essential for cellular proliferation, and dysregulation of its activity can lead to uncontrolled cell division, contributing to cancer development. Additionally, Cdk6 is subject to regulation by specific inhibitors, such as p18 and p19, which can bind to both free and cyclin-bound forms of Cdk6, thereby modulating its activity and ensuring that cell cycle progression occurs in a controlled manner. Cdk6 (H-11) antibody serves as an invaluable tool for researchers studying cell cycle dynamics and the molecular mechanisms underlying cell proliferation and cancer.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Cdk6 Antibody (H-11) References:
- The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. | Wang, H., et al. 2017. Nature. 546: 426-430. PMID: 28607489
- CDK6 inhibits white to beige fat transition by suppressing RUNX1. | Hou, X., et al. 2018. Nat Commun. 9: 1023. PMID: 29523786
- CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia. | Liu, W., et al. 2020. Front Genet. 11: 600227. PMID: 33597968
- Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. | Ishio, T., et al. 2022. Blood. 139: 1541-1556. PMID: 34818414
- miR-342-3p Suppresses glioblastoma development via targeting CDK6. | Yao, J., et al. 2022. Acta Biochim Pol. 69: 393-397. PMID: 35616621
- CDK6 activity in a recurring convergent kinase network motif. | Gangemi, CG., et al. 2023. FASEB J. 37: e22845. PMID: 36884374
- Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA. | Wang, C., et al. 2023. Bioorg Chem. 139: 106683. PMID: 37379778
- CDK6 is essential for mesenchymal stem cell proliferation and adipocyte differentiation. | Hu, AJ., et al. 2023. Front Mol Biosci. 10: 1146047. PMID: 37664186
- IGF2BP2 acts as a m6A modification regulator in laryngeal squamous cell carcinoma through facilitating CDK6 mRNA stabilization. | Tang, X., et al. 2023. Cell Death Discov. 9: 371. PMID: 37816718
- CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia. | Dinakaran, S., et al. 2024. Nat Cardiovasc Res. 3: 1301-1317. PMID: 39487364
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdk6 Antibody (H-11) | sc-271364 | 200 µg/ml | $322.00 | |||
Cdk6 Antibody (H-11): m-IgG3 BP-HRP Bundle | sc-550404 | 200 µg Ab; 40 µg BP | $361.00 | |||
Cdk6 (H-11) Neutralizing Peptide | sc-271364 P | 100 µg/0.5 ml | $69.00 |